Abstract:Children and adolescents hospitalized with infectious and inflammatory conditions are at risk of neurological sequelae, presenting clinicians with the formidable task of identifying those at greatest risk of morbidity. Francoeur et al 1 present an approach this challenge through the lens of pediatric neurocritical care. In their secondary analysis of the pediatric Global Consortium Study of Neurologic Dysfunction in COVID-19 (GCS-NeuroCOVID), they observed that severe neurological manifestations were strikingly common in hospitalized children and adolescents (ie, from birth to <18 years) with acute SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C), occurring in 18.0% and 24.8%, respectively. Acute encephalopathy accounted for most of the neurological sequelae in both conditions. The study demonstrated an association between severe neurological manifestations and new functional or neurocognitive morbidity, as measured by the Functional Status Scale and the Pediatric Cerebral Performance Category scale. This pivotal study applies a robust definition of severe neurological manifestations, determined by expert consensus, to a large international cohort of hospitalized young patients. The resulting analysis highlights the strengths and also some limitations of such datasets, underscoring the need to better understand risk factors for and downstream consequences of neurological sequelae in hospitalized children and adolescents. This report provides evidence that individuals younger than 18 years with preexisting neurological conditions are more likely to develop severe neurological manifestations of both acute SARS-CoV-2 infection and MIS-C. Overall severity of systemic illness may partially explain these findings, given that children with chronic neurological disorders are known to be at increased risk of severe COVID-19. 2 These analyses underscore a critical need for vigilant neurological monitoring in this vulnerable population. Underlying seizure disorders may be of particular significance in the GCS-NeuroCOVID cohort. In the case of acute SARS-CoV-2, seizures or status epilepticus constituted over 40% of severe neurological manifestations reported. In a previous large cohort study, children and adolescents with neurological sequelae of COVID-19 and MIS-C were more likely to have preexisting seizure disorders. 3 While the proportion of the GCS-NeuroCOVID cohort that had an underlying seizure disorder was not known, the study highlights a need for enhanced awareness of the risk of seizures and potential subsequent neurocognitive and functional impairment. Clinical, laboratory, and radiological observations from this study may reflect pathobiological mechanisms underlying neurological manifestations of acute infectious and inflammatory conditions such as SARS-CoV-2 and MIS-C. Lower platelet counts were seen in patients with severe neurological manifestations with both acute SARS-CoV-2 infection and MIS-C. This finding could represent a marker of overall disease severity, an interpretation that would align with a previously observed association between lower platelet count and mortality in adults with COVID-19. 4 Median observed platelet counts did not meet the threshold for thrombocytopenia, potentially indicating a more nuanced relationship between neurological manifestations and platelet number or possibly function. Immunomodulator and antiviral therapies (ie, corticosteroids, remdesivir, and intravenous immunoglobulin) were given in larger proportions to patients with acute neurological manifestations. One possible interpretation is that these therapies are given to children with greater overall disease severity. Alternatively, the presence of neurological complications might have influenced the decision to use these interventions. Taken together, these differences in platelet counts and immunomodulator therapies may implicate inflammatory mechanisms leading to neurological disease. A recent proteomic investigation identified evidence of endothelial and platelet activation in serum from patients with SARS-CoV-2–related inflammation. 5 This observed inflammatory signature might partially explain the neurovascular injuries seen in COVID-19. In the GCS-NeuroCOVID cohort, abnormal magnetic resonance imaging findings were more common in patients with acute SARS-CoV-2 with severe neurological manifestations than in those without. In pediatric sepsis, abnormal magnetic resonance imaging findings—predominately white matter signal changes and ischemia—are associated with mortality and new neurological disability. 6 Future descriptions of the specific patterns of abnormal imaging in the GCS-NeuroCOVID cohort could yield greater insight into mechanisms of acquired brain injury in children with SARS-CoV-2. Elucidating these mechanisms could lead to improved recognition of individ -Abstract Truncated-

Severe Pediatric Neurological Manifestations With Acute SARS-CoV-2 Hospitalization and Morbidities

Severe Neurological Manifestations in Pediatric Patients with SARS-CoV-2 or MIS-C

Association of SARS-CoV-2 infection with neurological impairments in pediatric population: A systematic review

Neurological complications in pediatric patients with SARS-CoV-2 infection: a systematic review of the literature

Children with severe neurological symptoms associated with SARS-CoV-2 infection during Omicron pandemic in China

Neuroimaging manifestations in children with SARS-CoV-2 infection: a multinational, multicentre collaborative study

Neurological diagnoses in hospitalized COVID-19 patients associated with adverse outcomes: A multinational cohort study

Clinical characteristics, treatment and prognosis of children with SARS-CoV-2 infection complicated with severe neurological dysfunctions in Foshan, China

Pediatric neuroimaging findings and clinical presentations of COVID-19: A systematic review

Neurological Complications in Children Hospitalized With Seizures and Respiratory Infections: A Comparison Between SARS-CoV-2 and Other Respiratory Infections

Characteristics and Outcomes of Children With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Admitted to a Quaternary Hospital: A Single-Center Experience

Long-term outcomes of hospitalized patients with SARS-CoV-2/COVID-19 with and without neurological involvement: 3-year follow-up assessment

Characteristics of children admitted to hospital with acute SARS-CoV-2 infection in Canada in 2020

Neurological symptoms and signs associated with COVID-19 in pediatric patients: a single-center experience

A systematic review and clinical presentation of central nervous system complications of SARS-CoV-2 in hospitalized pediatric patients during the COVID-19 pandemic in Israel

Neuropathology of Pediatric SARS-CoV-2 Infection in the Forensic Setting: Novel Application of Ex Vivo Imaging in Analysis of Brain Microvasculature

Anti-SARS-CoV-2 and Autoantibody Profiles in the Cerebrospinal Fluid of 3 Teenaged Patients With COVID-19 and Subacute Neuropsychiatric Symptoms

[Clinical and imaging analysis of neurological complications in critically ill children infected with SARS-CoV-2 Omicron]

Immune-mediated neurological syndromes in SARS-CoV-2-infected patients

Post-discharge outcomes of hospitalized children diagnosed with acute SARS-CoV-2 or MIS-C

Long-Term Growth and Neurodevelopmental Outcomes of Neonates Infected with SARS-CoV-2 during the COVID-19 Pandemic at 18–24 Months Corrected Age: A Prospective Observational Study